ArticleOrphanet journal of rare diseases2025
Complications and recurrence risks after endoscopic resection of digestive neuroendocrine tumors: a retrospective study.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeri-and postoperative complications and recurrences are associated with the endoscopic surgical procedures for neuroendocrine tumors of the digestive system. This study aimed to evaluate the long-term outcomes and safety of endoscopic submucosal dissection and mucosal resection for neuroendocrine tumors in the digestive system.
methodsIn a retrospective cohort study, variables of minimally invasive endoscopic treatments and follow-up recurrences of 100 males and females with neuroendocrine tumors of gastric, duodenal, and rectal lesions were collected from records and analyzed. The curative resection criteria were followed the European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopic ultrasound (EUS) and/or biopsy with histological assessment) routinely performed on all lesions included in this study for lesion confirmation prior to endoscopic resection.
resultsTumor size from 6 to 11.3 mm and endoscopic surgery procedure time from 6 to 13 min were reported. Forty-nine, 44, and seven lesions were located in the gastric, rectal, and duodenal regions, respectively. Six (6%), 4 (4%), 16 (16%), and 5 (5%) patients reported bleeding, perforation, nausea, and vomiting, respectively, due to the surgical procedure(s). Five patients (5%) underwent recurrent endoscopic surgery. Local recurrences occurred in three (3%; two (2%) of gastric lesions and one (1%) of duodenal lesions; all grade 1) patients, and distal metastases occurred in two (2%) patients. None of the patients died during the follow-up period. Before surgery, grade 2 (p = 0.049), tumor size ≥ 9.5 mm (p = 0.041), and gastric tract and rectal lesions (p = 0.021) were associated with local and/or distal metastases.
conclusionsThe prevalence of neuroendocrine tumors is high in the stomach and rectum, endoscopic resection may be safe, and high-grade tumors may be associated with a high risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.